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Diabetes mellitus is a major risk factor for ischemic heart disease (IHD). Patients with diabetes and IHD experience worse clinical
outcomes, suggesting that the diabetic heart may be more susceptible to ischemia-reperfusion injury (IRI). In contrast, the animal
data suggests that the diabetic heart may be either more, equally, or even less susceptible to IRI. The conﬂicting animal data may
be due to the choice of diabetic and/or IRI animal model. Ischemic conditioning, a phenomenon in which the heart is protected
against IRI by one or more brief nonlethal periods of ischemia and reperfusion, may provide a novel cardioprotective strategy for
thediabeticheart.Whetherthediabeticheartisamenabletoischemicconditioningremainstobedeterminedusingrelevantanimal
models of IRI and/or diabetes. In this paper, we review the limitations of the current experimental models used to investigate IRI
and cardioprotection in the diabetic heart.
1.Introduction
Ischemic heart disease (IHD) is the leading cause of death
and disability in the UK. Diabetes mellitus is a major risk
factor for IHD patients with diabetes who are 2-3 times
more likely to develop IHD [1]. Diabetes mellitus (DM), in
general, is a condition where the body cannot adequately
control its level of glucose. There are two types of diabetes,
type I diabetes and type II diabetes. Type I diabetes is
characterized by the inability of the body to produce insulin;
this is caused by cellular-mediated programming of the
autoimmune system and subsequent destruction of pancre-
atic beta-cells, the cells responsible for insulin production.
The prevalence of this form of diabetes is relatively low and
usually starts early in life [2]. Whereas type II diabetes is
known as the insulin resistant form, insulin is produced
however the target tissues become insensitive or resistant
to the action of insulin thereby not utilizing blood glucose
correctly and as a consequence increasing circulating blood
g l u c o s el e v e l s[ 3]. This form accounts for a high percentage
of all diabetes and is historically more common in older age
groups;howevertheprevalenceoftypeIIdiabetesinchildren
and young adults is also increasing especially in westernized
societies [4].
There are many features of the diabetic heart that can
contribute to an increased susceptibility to IHD, these
include diabetic cardiomyopathy and angiopathy [5]. Dia-
betic cardiomyopathy is a disease that aﬀects the myo-
cardium in diabetic patients, causing structural changes
which lead to abnormal functionality of the heart. These
changes can eventually result in left ventricular hypertrophy
(LVH) and diastolic/systolic dysfunction [6]. Changes at
the molecular level occur in the diabetic heart leading to
thisphenotype,includingendothelialdysfunction,metabolic
perturbations, and diﬀerences in cellular signaling, which
are well described in an extensive review by Hayat et al.,
2004 [6]. Diabetic angiopathy causes vascular complications
in chronic diabetic patients and can be classiﬁed into two
types: microangiopathy and macroangiopathy [7]. Diabetic
microangiopathy is the term coined to describe the damage
caused to small blood vessels and capillaries within the body
as a consequence of chronic hyperglycemia. This damage can
lead to a decreased supply of oxygen and vital substrates to
the tissues, which can lead to adverse clinical outcomes such2 Cardiology Research and Practice
as retinopathy, nephropathy, neuropathy, and diabetic foot
[8]. Macroangiopathy as a consequence of diabetes mainly
involves an accelerated form of atherosclerosis [9], another
risk factor for CV disease. It aﬀects the larger blood vessels
within the body, where development and progression of
atheroscleroticplaquesleadtostenosisorocclusions,impair-
ing blood ﬂow [10]. Diabetic complications, atherosclerosis,
hypertension,andmanyotherCVriskfactorssuchasobesity
can all interact and render the heart more susceptible to IHD
[11].
Theincidenceofdiabetesisincreasingatanalarmingrate
throughout the world. Globally, the estimated prevalence
of diabetes for 2010 was 285 million and is expected to
aﬀect 438 million people by 2030 [1]. In the UK, there are
2.6 million people who have been diagnosed with diabetes
(2009) which equates to a 4.1% average prevalence and it is
estimated that 4 million people will be diabetic by 2025 [12].
The major consequence of IHD results from the detri-
mental eﬀect of acute myocardial ischemia-reperfusion
injury (IRI). IRI is a paradoxical event that occurs in
the myocardium. Brieﬂy, when blood ﬂow is reduced due
to myocardial ischemia, the best treatment strategy is to
reestablish blood ﬂow to the damaged area, however this
return in blood ﬂow causes damage [13]. Patients with
diabetes experience worse clinical outcomes in a number
of clinical settings of acute IRI including acute myocardial
infarction (MI) [14–16], coronary angioplasty [16], and
cardiac bypass surgery [17–19]. This clinical data suggests
that the diabetic heart may be more susceptible to acute
IRI. In contrast, the animal data is inconclusive with
experimental studies suggesting that the diabetic heart may
be more, equally or even less susceptible to acute IRI [20].
However, one major reason for the disparity between the
clinical and animal data may be due to the choice of IRI
and/or diabetic animal model used in the animal studies
[20].
Given the worse clinical outcomes in diabetic patients
with IHD, novel therapeutic strategies for protecting the
diabetic heart against the detrimental eﬀects of acute IRI are
required to improve clinical outcomes in this patient group.
Extensive research has investigated protecting the heart from
IRI using conditioning strategies, either by mechanically
activatingcellsurvivalpathwaysbyischemicpreconditioning
(IPC) [21] and remote ischemic conditioning (RIC) [22]
or pharmacologically using cardioprotective agents [23].
Ischemic conditioning is an endogenous phenomenon in
which one or more brief cycles of nonlethal ischemia and
reperfusion applied directly to the heart protects itself from
a sustained lethal episode of acute IRI [24]. Furthermore
exciting research in the area of RIC, whereby an alternative
organ to the heart, for example, the arm, can be made
ischemic by one or more brief cycles of nonlethal ischemia
and reperfusion using a blood pressure cuﬀ, can limit the
damage caused by a sustained ischemic insult [22]a n d
this may provide a novel cardioprotective approach for the
diabetic heart. These strategies are further described in
Section 4. However, in order to translate ischemic condi-
tioning into the clinical arena for the beneﬁt of diabetic
patients, it is important to ﬁrst determine in animal studies
whether the diabetic heart is amenable to cardioprotection
elicited by ischemic conditioning. To achieve this requires
the use of appropriate animal models of IRI and diabetes
which also take into account other comorbidities such as age,
dyslipidemia,andhypertension,factorswhichalsoimpacton
the ability to ischemic condition the heart [25].
The aim of this paper will be to highlight the limitations
of currently used animal models of IRI and diabetes as a
potential explanation for the disparity that exists between
clinical and experimental data, with regard to the sus-
ceptibility of the diabetic heart to IRI and endogenous
cardioprotection.
2. AnimalModels of Diabetes
Animal models used to investigate diabetes have been
created using a variety of diﬀerent methods such as the
administrationofdrugstoxictothepancreas,modiﬁeddiets,
inbreedingofspontaneousmutations,orgeneticengineering
[34]. This has resulted in the availability of many diﬀerent
diabetic animal models [35]. In addition, the diabetic status
induced by these methods needs to be assessed with caution
as none of the models accurately and completely reﬂect the
human pathology of diabetes.
For example, type I diabetes is characterized by insulin
deﬁciency as a consequence of autoimmune destruction of
pancreatic β cells in the islets of Langerhans [36]. This
disease is mimicked by administration of streptozotocin
(STZ). However, this is an alkylating agent based nitrosourea
derivative [37], which interferes with numerous cellular
processes such as glucose transport, glucokinase function
and can also induce DNA strand breaks [38]. This toxic
compound can be given either as a single high dose to induce
diabetes but this is associated with high mortality. Therefore,
it is more common to use a series of low doses to induce
diabetes in rodents [39]. Alloxan is a toxic glucose analogue,
whichpreferentiallyaccumulatesinbetacellsofthepancreas,
causing excessive production of hydroxyl free radicals and
destruction of the beta-cells hence mimicking type I diabetes
[40]. In essence, the primary etiopathology caused by these
experimental approaches has little autoimmune component
and does not truly reﬂect the pathogenesis leading to type
I diabetes in the human [39]. Therefore, it could be argued
that the translation of ﬁndings from this particular animal
model of type I diabetes to the clinical setting may be
problematic.
Type II diabetes in humans is a metabolic disorder and
normallyarisesduringadulthood[41].Agoodanimalmodel
of type II diabetes is the Goto-Kakizaki (GK) rat, which
originates from the inbreeding of Wistar rats that exhibited
hyperglycemia. The GK rat spontaneously becomes diabetic
early in life, showing glucose insensitivity in their pancreatic
beta cells [42] with the diabetic status increasing with age
[43]. The Otsuka Long Evans Tokushima Fatty (OLETF) rat
originates from the inbreeding of Long-Evans rats which
exhibit glucose intolerance [44]; these rats are mildly obese
and the diabetic phenotype is more dramatic in males. Both
the Zucker diabetic fatty (ZDF) rat [45] and the db/db mice
[46] are models that express other comorbidities such asCardiology Research and Practice 3
obesity and dyslipidemia as well as glucose intolerance [47].
For a thorough review into animal models in diabetes please
refer to [34].
3.The Susceptibility of the Diabetic Heart to
Acute IRI
Despite the clinical data suggesting that the diabetic heart
is more susceptible to acute IRI, the animal data has been
conﬂicting with experimental studies showing more, equal,
or less sensitivity to acute IRI. The reasons for this disparity
between the animal and clinical data were the subject of
a review in 1997 by Paulson, who concluded that the
sensitivity of the diabetic heart to acute IRI was dependent
on the animal models and conditions used. The diabetic
heart was shown to be less sensitive to acute IRI in studies
which (i) used a short duration of diabetes (<6w e e k s ) ;
(ii) used glucose as the only substrate; (iii) used a no-
ﬂow IRI protocol, whereby global ischemia is initiated by
total interruption of the perfusate to the heart. Whereas, if
diabetes was more prolonged and severe, fatty acids were
present in the perfusate and a low-ﬂow IRI protocol was
used that is, experimental protocols which reﬂect the clinical
scenario better, the diabetic heart was found to be more
sensitive to IRI [20]. We have reviewed the literature since
1997, and the same pattern emerges (see Tables 1, 2,a n d3).
However, to this we need to add another complicating factor,
the choice of IRI model and the lack of other comorbidities
such as age, dyslipidemia, and hypertension, factors which
are critical when investigating cardioprotection.
Numerous endogenous factors contribute to myocardial
IRI. These include production of reactive oxygen species
(ROS), changes in the intracellular calcium and pH, trig-
gering of inﬂammatory mechanisms; all of which interact
with each other to mediate opening of the mitochondrial
permeability transition pore (PTP), leading to eventual car-
diomyocyte death (Figure 1)[ 13]. Interestingly, the patho-
logicalchangesalreadyoccurringindiabeticcardiomyopathy
include increased release of ROS [59], abnormal handling
of calcium, and increased release of inﬂammatory mediators
[60]; this experimental information alongside the evidence
that diabetic patients have a worse prognosis following
myocardial infarction [61], strongly suggest that the diabetic
heart should be more vulnerable to damage. However, a
plethora of experimental and clinical studies demonstrated
a variety of outcomes, which could be highly dependent on
the animal model, experimental protocol, and severity of
diabetes. In Figure 2, we attempt to summarize the possible
mechanisms that make the diabetic heart more or less
susceptible to infarction following ischemia reperfusion.
3.1. Animal Models of Type I Diabetes. Av a s ta m o u n to f
research has been performed in order to assess the sensitivity
to myocardial ischemic damage in models of type I diabetes.
In vivo [53, 56]a n dex vivo [58] investigations using a
STZ-rat model demonstrated that acute diabetes (1–4 weeks
of STZ treatment) resulted in less susceptibility to acute
IRI. However, if STZ treatment was increased to longer
than 6 weeks, the sensitivity to acute IRI was increased.
pH restoration
Apoptosis/cell
death
Myocardial reperfusion
Ischaemia
↑Cyto c
Ca2+↑
ROS↑
Na+↑
Mito Ca2+ ↑mPTP
ATP↓
↑Inﬂammatory
mediators
Figure 1:Endogenousfactorscontributingtoischemia-reperfusion
injury. Following ischemia, blood ﬂow is reestablished in the
myocardium. The myocardium is subject to a number of abrupt
changes during the transition from ischemia to reperfusion.
Both biochemical and metabolic alterations occur including the
generation of reactive oxygen species (ROS), decrease in ATP levels,
an increase in inﬂammatory mediators, the rapid restoration of
physiological pH, which in turn increases intracellular sodium
and overload of intracellular calcium and mitochondrial calcium.
These factors interact with each other to mediate reperfusion injury
through the opening of the mitochondrial permeability transition
pore (mPTP) and initiation of cell death pathways [13].
Ma et al. [56] found increased phosphorylation of the
prosurvival kinase Akt and decreased levels of caspase-3,
vascular endothelial growth factor (VEGF), and nitric oxide
(NO) following 2 weeks STZ induction but the opposite
ﬁnding following 6 weeks treatment, supporting the loss
of the cardioprotective state after 6 weeks [56]. Nawata et
al. (2002) [51] also found that 4 weeks of STZ-induced
diabetes reduced sensitivity to acute IRI in the Langendorﬀ-
perfused isolated heart model [51]. This phenomenon of
protection in the acute diabetic setting was also present in
alloxan-induced diabetes in Yucatan pigs [57]. Following 1
hour of regional coronary artery occlusion and reperfusion
the in vivo myocardial infarct size was smaller compared to
controlandthiswasaccompaniedbyanincreasedexpression
of cell survival proteins. Of note, global left ventricular
function was worse in diabetes; however function within the
area at risk was better [57]. In a cardiomyocyte model of
diabetes, cells were incubated for 3 days with either 5mM or
25mM glucose in the medium. High-glucose treatment was
protective against simulated IRI. The high-glucose treatment
caused a reduction in necrosis, apoptosis, and calcium
content, whereas the antiapoptotic protein bcl-2 increased
and proapoptotic bad was shifted to its inactive state [49]i n
the presence of 25mM glucose.
In contrast to this data, showing that “acute” or short-
term induced type I diabetes is cardioprotective compared
to the longer-term induction, Hadour et al. (1998) [48]
induced diabetes in rabbits for 8 weeks using alloxan, then4 Cardiology Research and Practice
Table 1: Studies indicating the diabetic heart is more sensitive to ischemic injury compared to normoglycemic controls.
Study Model Ischemic protocol Duration/onset
of diabetes Substrates Model of
diabetes End points
Jones et al.
(1999) [26] db/db mouse
In vivo non recovery,
30min regional
ischemia/2h
reperfusion
In-bred strain In vivo substrates Type II
diabetes Infarction
Kersten et al.
(2000) [27]
Dog, Alloxan (40mg/kg)
and STZ (25mg/kg)
In vivo non recovery,
60min regional
ischemia/3h
reperfusion
3w e e k s In vivo substrates Type I
diabetes Infarction
Kersten et al.
(2000) [27]
Dog, Dextrose 15% to
cause acute
hyperglycaemia
In vivo non recovery,
60min regional
ischemia/3h
reperfusion
70mins In vivo substrates Type I
diabetes Infarction
Lefer et al.
(2001) [28] db/db mouse
In vivo non recovery,
30min regional
ischemia/2h
reperfusion
In-bred strain In vivo substrates Type II
diabetes Infarction
Fiordaliso et
al. (2001)
[29]
Rat cardiomyocytes —
1, 2, and 4 days
of 25mmol/L
incubation in
medium
— Type I
diabetes Cell death
Marfella et al.
(2002) [30]
Sprague-Dawley Rat, STZ
(70mg/kg i.v)
In vivo non recovery,
25min regional
ischemia/2h
reperfusion
9d a y s In vivo substrates Type I
diabetes
Infarction and
protein expression
Marfella et al.
(2002) [30]
Sprague-Dawley Rat,
isolated heart
Langendorﬀ isolated
heart, 25min regional
ischemia/2hr
reperfusion
— 33.3mmol/L
glucose
Type I
diabetes
Infarction and
protein expression
Ebel et al.
(2003) [31]
Rabbit- 50% Dextrose
infused 30min prior to
ischemia until reperfusion
normoglycaemic
rat-under intravenous
In vivo non recovery,
30min regional
ischemia/2h
reperfusion
hyperglycemia
of 600 mgd1-1
throughout
ischemia
In vivo substrates Type I
diabetes Infarction
Su et al.
(2007) [32]
infusion at a rate of
4mL·kg–1·h–1: of
glucose 500g/l during
ischemia, saline during
reperfusion
In vivo non recovery,
30min regional
ischemia/6h
reperfusion
— In vivo substrates Type I
diabetes
Infarction, apoptosis
and kinase
expression
Desrois et al.
(2010) [33]
Aging Goto Kakizaki Rat,
male
Langendorﬀ isolated
heart, 32min low
ﬂow global
ischemia/32min
reperfusion
In-bred strain
1.2mM
palmitate, 3%
albumin, 11mM
glucose, 3 U/l
insulin, 0.8mM
lactate, and
0.2mM pyruvate.
Type II
diabetes Myocardial function
subjectedtheheartstoinvivo30minutemyocardialischemia
and 3 hours reperfusion and saw a reduction in MI size
compared to control nondiabetic rabbits. Conversely, in
nondiabetic rabbits infused with high glucose throughout
myocardialischemiaandreperfusiontomimicacutediabetes
no diﬀerence in infarction was seen compared to controls.
They suggested that the presence of type I diabetes in the
rabbit induced a chronic and metabolic cardioprotective
state in the heart [48]. Ebel et al. [31] showed in the same
model of alloxan-induced diabetes in rabbits that 6-weeks
duration of diabetes had no inﬂuence on the vulnerability
to IRI compared to controls, further supporting the theory
of a chronic (greater than 6 weeks) protected state in this
model [31]. Chronic administration of STZ for 12 weeks
in rats also showed a decreased susceptibility to MI [52].
Diabetic hearts had greater left ventricular function and
the incidence of ventricular ﬁbrillation and creatine kinase
(CK) release were decreased. This was accompanied byCardiology Research and Practice 5
Table 2: Studies indicating the diabetic heart is less sensitive to ischemic injury compared to normoglycaemic controls.
Study Model Ischemic Protocol Duration/onset of
diabetes Substrates Model of
diabetes End points
Hadour et al.
(1998) [48]
Rabbit, alloxan
(100mg/kg)
In vivo nonrecovery,
30min regional
ischemia/3hr
reperfusion
2m o n t h s In vivo
substrates
Type I
diabetes Infarction
Schaﬀer et al.
(2000) [49]
Rat, neonatal
cardiomyocytes
10mM deoxyglucose
and and 3mM
amobarbital medium
f o r1h r ,O Rh y p o x i c
chamber: 2.3% O2–5%
CO2-balance N2 for
1hr
3-day incubation
with 25mM
glucose in
medium
— Type I
diabetes Infarction
Oliveria et al.
(2001) [50]
Goto Kakizaki Rat,
male, isolated
cardiomyocyte
mitochondria
— In-bred strain — Type II
diabetes
Cell death and
mPTP
Nawata et al.
(2002) [51]
Rat, STZ
(65mg/kg)
Langendorﬀ isolated
heart, 30min low ﬂow
global ischemia/30min
reperfusion
4w e e k s 11mmol/L
glucose
Type I
diabetes
Myocardial
function
Ooie et al.
(2003) [52]
Rat, STZ
(65mg/kg)
Langendorﬀ isolated
heart: Low-ﬂow global
ischemia for 5min,
followed by no-ﬂow
ischemia for 25min.
30min reperfusion
12 weeks 11mmol/L
glucose
Type I
diabetes
Myocardial
function, creatine
kinase release
Ravingerov´ ae t
al. (2003) [53]
Rat, STZ
(45mg/kg)
In vivo non recovery,
30min regional
ischemia/4hr
reperfusion
1w e e k In vivo
substrates
Type I
diabetes Infarction
Kristiansen et al.
(2004) [54]
Goto Kakizaki Rat,
male
Langendorﬀ isolated
heart, 50min regional
ischemia/2hr
reperfusion
In-bred strain 11mmol/L
glucose
Type II
diabetes Infarction
Kristiansen et al.
(2004) [54]
Obese Zucker
Diabetic Fatty Rat,
male
Langendorﬀ isolated
heart, 50min regional
ischemia/2hr
reperfusion
In-bred strain 11mmol/L
glucose
Type II
diabetes Infarction
Tsang et al.
(2005) [55]
Goto Kakizaki Rat,
male
Langendorﬀ isolated
heart, 30min regional
ischemia/2hr
reperfusion
In-bred strain 11mmol/L
glucose
Type II
diabetes
Infarction, kinase
expression
Ma et al. (2006)
[56]
Rat, STZ
(50mg/kg)
In vivo non recovery,
30min regional
ischemia/2hr
reperfusion
2w e e k s In vivo
substrates
Type I
diabetes Infarction
Chu et al.
(2010) [57]
Yucatan pigs,
alloxan
(200mg/kg)
In vivo non recovery,
1hr regional
ischemia/2hr
reperfusion
5w e e k s In vivo
substrates
Type I
diabetes
Infarction and
protein expression
Shi-Ting et al.
(2010) [58]
Rat, STZ
(60mg/kg)
Langendorﬀ isolated
heart, 30min regional
ischemia/40min
reperfusion
4w e e k s 11mmol/L
glucose
Type I
diabetes
Infarction and
creatine kinase
release6 Cardiology Research and Practice
Table 3: Studies indicating no diﬀerence in the sensitivity of the diabetic heart to ischemic injury compared to normoglycemic controls.
Study Model Ischemic Protocol Duration/onset
of diabetes Substrates Model of
diabetes End points
Hadour et al.
(1998) [48]
Rabbit, 10%
glucose infusion to
300mg/dL blood
glucose
In vivo nonrecovery,
30min regional
ischemia/3hr
reperfusion
Blood glucose
maintained at
300mg/dL
throughout
procedure
In vivo
substrates
Type I
diabetes Infarction
Tanaka et al.
(2002) [62]
Dog, alloxan
(40mg/kg) and
STZ (25mg/kg)
In vivo nonrecovery,
60min regional
ischemia/3hr
reperfusion
3w e e k s In vivo
substrates
Type I
diabetes Infarction
Ravingerov´ a
et al. (2003)
[53]
Rat, STZ
(45mg/kg)
In vivo nonrecovery,
30min regional
ischemia/4hr
reperfusion
8w e e k s In vivo
substrates
Type I
diabetes Infarction
Ebel et al.
(2003) [31]
Rabbit- alloxan
(100mg/kg)
In vivo nonrecovery,
30min regional
ischemia/2hr
reperfusion
6w e e k s In vivo
substrates
Type I
diabetes Infarction
Desrois et al.
(2004) [63]
Aged Goto
Kakisaki Rat, male
Langendorﬀ isolated
heart, 32min low
ﬂow global
ischemia/32min
reperfusion
In bred strain 11mmol/L
glucose
Type II
diabetes
Myocardial
function
Ma et al.
(2006) [56]
Rat, STZ
(50mg/kg)
In vivo nonrecovery,
30min regional
ischemia/2hr
reperfusion
6w e e k s In vivo
substrates
Type I
diabetes Infarction
Bulhak et al.
(2009) [64]
Goto Kakizaki Rat,
male
In vivo nonrecovery,
35min regional
ischemia/2hr
reperfusion
In bred strain In vivo
substrates
Type II
diabetes Infarction
Matsumoto
et al. (2009)
[65]
Goto Kakizaki Rat,
male
In vivo nonrecovery,
30min regional
ischemia/2hr
reperfusion
In bred strain In vivo
substrates
Type II
diabetes Infarction
Shi-Ting et
al. (2011)
[58]
Rat, STZ
(60mg/kg)
Langendorﬀ isolated
heart, 30min regional
ischemia/40min
reperfusion
8w e e k s 11mmol/L
glucose
Type I
diabetes
Infarction and
creatine kinase
release
a persistent translocation of protein kinase C-ε (PKC-ε),
a modulator of the mitochondrial permeability transition
pore,duringischemiabutonlyinthediabetichearts.Follow-
ing these results, the authors suggested that in STZ-induced
diabetes PKC-ε plays a crucial role in the susceptibility to
MI [52]. However, this investigation was performed using
aL a n g e n d o r ﬀ-perfused model of no ﬂow ischemia and
contained no added substrates. It would be interesting to
assess translocation properties of PKC-epsilon in the in vivo
setting.
Other investigators have also shown that acute initiation
of type I diabetes does not inﬂuence the susceptibility to
MI. Both alloxan and STZ-treated dogs, although at a lower
dose to previously mentioned investigations, reported no
diﬀerence in MI size following IRI in vivo [62].
However, in other studies, type I diabetes has been
shown to render the heart more susceptible to IRI. It has
been suggested that hyperglycemia has a negative impact on
endogenous cardioprotective signaling. Kersten et al. [27]
showedthathyperglycemiaindogs,inducedeitheracutelyby
15% dextrose prior to IRI in vivo, or in chemically induced
diabetes (3 weeks STZ), increased MI size. Interestingly,
the studies mentioned above suggested that “acute” diabetes
would render the heart less susceptible to diabetes. However,
those studies were in rodent models of diabetes and had
a shorter duration of IRI. Ebel et al. [31]r e c o r d e da
greater susceptibility to MI in their rabbit model following
an infused solution of 50% dextrose 30 minutes prior to
ischemia in vivo to elicit a hyperglycemic state of 600mg/dL
[31]. Su et al. [32] used an infused glucose model to elicitCardiology Research and Practice 7
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Figure 2: Possible mechanisms that make the diabetic heart more or less susceptible to infarction following ischemia reperfusion. (A)
Diabetes can render the heart more susceptible to infarction. (A1) A diabetes-associated increase in the activity of p53, leading to the
initiation of cell death pathway [29]. (A2) High-glucose causes a decrease in the activity of transcription factor HIF-1α, a subsequent
downregulation of VEGF and less revascularization following ischemia [66]. This results in cell death and larger infarct volume. (B) Diabetes
can protect the heart against infarction. (B1) Hyperglycaemia is cardioprotective due to the increased availability of glucose which is the
hearts preferred substrate in times of stress. (B2/3) The Na+/Ca2+ and Na+/H+ exchangers in the diabetic heart reportedly have decreased
activity; therefore the diabetic heart accumulates less of these ions preventing overload and the associated detrimental eﬀects [20]. (B4)
Diabetes is associated with an increased release of reactive oxygen species (ROS); a possible subsequent release of free radical scavenging
enzymes increase the level of antioxidants within the myocardium protecting the heart from the consequence of IRI [20]. (B5) An increased
basal level of prosurvival kinases in diabetes [57]. (B6) PKC-ε increases in diabetes, activating the mitochondrial KATP channel causing
subsequent reduction in calcium accumulation and increasing ATP synthesis. PKC-ε also persistently translocate during ischemia but only
in diabetic hearts [52]. (B7) High glucose caused reduction in cell death proteins and increased anti apoptotic bcl-2 [49].
hyperglycemia in rats, this also rendered the heart more
susceptible to MI of note the reperfusion time following
ischemia in this study was notably longer compared to other
rodent models [32]. With regard to the possible mechanism,
hyperglycemia in rat cardiomyocytes was shown to promote
p53-dependent activation of apoptosis [29].
Marfella et al. [30] also examined the eﬀect of hyper-
glycemia and STZ-induced diabetes on MI size in rats,
both in vivo and ex vivo. Both hyperglycemic conditions
caused an increase in MI size, together with a decreased
transactivation of the hypoxic inducible factor HIF-1α [30].
The diabetic induction in this model was 9 days prior to
the ischemic episode, although an increased dose of STZ
(70mg/kg) was used. HIF-1α controls the upregulation of
vascular endothelial growth factor (VEGF) in response to
hypoxia, initiating neovascularization following ischemia. If
thisaxisisimpaired,asseemsthecaseindiabetes,inadequate
revascularization will occur resulting is potential worse
outcomes for the diabetic patient [66].
3.2. Animal Models of Type II Diabetes. In 2004, Kristiansen
et al. [54] were the ﬁrst to investigate the susceptibility to
acute IRI and ischemic conditioning (IPC) in a model of
type II diabetes. Two distinct models: the GK rat and ZDF
rat showed in Langendorﬀ-perfused isolated hearts (with
no added substrates), that MI size was smaller than their
respective nondiabetic controls. Interestingly, even though
these hearts appeared to be more resistant to ischemic
damage, they were not amenable to protection by IPC [54].
Desrois et al. performed two separate studies also using the
ex vivo Langendorﬀ preparation in the GK rat in 2004 [63]
and 2010 [33]. In 2004, they compared gender diﬀerence
within diabetes and the eﬀect this has on the susceptibility
to MI. The preparation involved perfusing the hearts with8 Cardiology Research and Practice
Krebs-Hensleit buﬀer with no added substrates. They found
that female hearts had larger MI size than the male GKs and
that no signiﬁcant diﬀerence was noted between male hearts
of the diabetic and nondiabetic controls [63]. Interestingly,
their study in 2010 again utilized the Langendorﬀ technique,
and showed that the male GK heart was more susceptible
to MI than the control heart [33]. The latter investigation
included additional fatty acid substrates in the perfusate,
similartothoselikelytobefoundintheinvivoscenario.This
may suggest that in the setting of type II diabetes, substrates
found in the blood could play an important role in cell
damage.Studiesindb/dbmiceinvivo supportthisidea;Lefer
et al. (2001) [28] and Jones et al. (1999) [26]b o t hs a wa
diabetes-associated increase in MI size.
Other studies show a similar result to Kristiansen et al’s
studyin2004[54].Tsangetal.(2005)usingtheisolatedheart
model, with no added substrates, however with a shorter
ischemic time, showed the heart of the GK rat to be less
susceptible to infarction than the Wistar rat control [55].
Supporting these ﬁndings, cardiomyocytes isolated from GK
rats were less susceptible to mPTP opening in response to
calcium, achieved by adding soluble Ca2+ to a phosphate-
containing medium. This was accompanied by a larger
calcium accumulation, leading to decreased opening of the
mitochondrial pore and reduced cardiomyocyte death [50].
Controversially, two recent investigations that have been
performedinvivo[64,65]intheGKratshowednodiﬀerence
in the susceptibility to infarct compared to control rats
following 30 or 35 minutes ischemia and 2-hour reperfusion.
Some blood components, such as platelets and neu-
trophils, have been suggested to play a role as mediators of
celldamagein ischemiaandreperfusion[20].Thisisanother
confounding factor when comparing data from cell, in vitro
andinvivoexperiments.ThesensitivityofthetypeIIdiabetic
heart in in vivo settings has had limited study compared to
type I diabetes, therefore more work is required to clarify
these initial ﬁndings.
4. Cardioprotectioninthe DiabeticHeart
4.1. Animal Models of IRI. T h eh e a r t ,a si na n yl i v i n g
tissue, has endogenous protective mechanisms which, when
activated, render it resistant to IRI, in other words the heart
can be “conditioned” [21]. Initial studies by Murry et al.
(1986) [24], showed that short bursts of ischemia followed
by reperfusion prior to a prolonged insult of ischemia and
reperfusion, were associated with a reduction in MI size
by 75%. This was termed “ischemic preconditioning” (IPC)
[24]. The phenomenon of IPC is highly reproducible in
all species [21]. Over the years, the phenomenon of IPC
has evolved to include pharmacological conditioning [68],
which involves targeting cellular mechanisms involved in IRI
or promoting those involved in IPC. Also, short bursts of
ischemia and reperfusion following an ischemic insult can
reduce MI size and this term was coined ischemic post-
conditioning (IPost) [69]. More recently, remote ischemic
conditioninghasbeendiscovered,wherebyanorganortissue
remote from the heart is conditioned and reduces infarct size
[22].
IPC reduces lethal cell injury in the ischemic myocar-
dium[24];howthisphenomenonworkshasbeenextensively
studied and is summarized in Figure 3. Brieﬂy, IPC causes
the release of G-protein-coupled receptor (GPCR) agonists
which bind to the receptor and activate numerous signaling
pathways. Phosphatidylinositol-3-kinase (PI3K) activation
can lead to activation of a number of downstream molecules
such as Akt, protein kinase C (PKC), extracellular regulated
kinase (ERK), nitric oxide synthase (NOS), and inactivation
of glycogen synthase kinase-3β (GSK-3β) .T h e s ec o n v e r g et o
activate the mitochondrial ATP-dependent potassium chan-
nel (KATP), closing the mitochondrial permeable transition
pore (mPTP) resulting in protection from IRI [67]. Before
IPC can be applied in the clinical setting it is important to
determinewhetherdiabeticheartisamenabletothisendoge-
nous cardioprotective strategy. The animal data suggests
that the diabetic heart is resistant to ischemic conditioning
such that the IPC stimulus needs to be increased to induce
cardioprotection [70].
Bouchard et al. (1998) [70] showed that in a STZ rat
model of diabetes, an IPC stimulus consisting of 1 cycle of
5-minute ischemia followed by 10-minute reperfusion (IPC-
1) was not suﬃcient to preserve the vasodilatory response to
5-HT suggesting an impairment of endothelial cells in the
diabetic heart and consequently the inability to generate and
release enough NO. However, when the IPC stimulus was
increased to 3 cycles of 5-minute ischemia followed by 5-
minute reperfusion (IPC-3) the vasodilatory response to 5-
HT was present. Furthermore, in the same investigation, 30-
minutepretreatmentwithadenosine,animportantmediator
in IPC [71], mimicked the cardioprotective outcome of
IPC-3, whereas 15-minute pretreatment was ineﬀective [70].
These ﬁndings suggested that signaling pathways activated
by adenosine either endogenously or exogenously may be
hindered in diabetic coronary vessels, but have the potential
to be recovered by an increased stimuli. The KATP channel
is involved in the mechanism of protection by IPC [72]a n d
adenosine [73]; studies in diabetic animals have reported
reduced sensitivity to KATP channel activators [74]w h i c h
could correlate with the need for an increased stimulus to
achieve KATP channel activation, subsequent mPTP inhibi-
tion, and reduction in apoptosis initiation hence reducing
m y o c a r d i a lc e l ld e a t h[ 75]. Another study using alloxan-
/STZ-induced diabetes in dogs also supported the role of
dysfunctional KATP channel in diabetes [76].
Other important endogenous mechanisms involved in
protection by IPC is the reperfusion injury salvage kinase
pathway (RISK) [77], with its main constituent the PI3K-
Akt axis. Tsang et al. (2005) [55] found that to protect
the myocardium in the Goto-Kakizaki rat model of type
II diabetes, an increased IPC stimulus was also required.
Similar to the previous study, 1 cycle of 5-minute ischemia
followedby10-minutereperfusionwasinsuﬃcienttoprotect
the heart; however 3 cycles of this protocol reduced infarct
volume considerably. They investigated the level of phospho-
rylated Akt (Akt-P) within the myocardium and found that
in the diabetic heart, an increased IPC stimulus is required
to achieve an essential level of Akt phosphorylation neces-
sary to mediate cardioprotection [55], thereby highlightingCardiology Research and Practice 9
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Figure 3: The cellular mechanisms involved in Ischemic Preconditioning. IPC, IPost, or pharmacological agents initiates the release of
G-protein-coupled receptor (GPCR) agonists which bind to the receptor and activate numerous signaling pathways. Phosphatidylinositol-
3-kinase (PI3K) and Ras activation can lead to activation of a number of downstream molecules such as Akt, protein kinase C (PKC),
extracellularregulatedkinase(ERK),nitricoxidesynthase(NOS),andinactivationofglycogensynthasekinase-3β (GSK-3β).Theseconverge
to activate the mitochondrial ATP-dependent potassium channel (KATP), closing the mitochondrial permeable transition pore (mPTP)
resulting in protection from IRI [67].
a diabetes-associated impairment in PI3K-Akt signaling.
Increasing the stimulus of IPC by increasing cycle number
appears important in diabetes; however, the duration of
the pre-ischemia/reperfusion protocol may also play a vital
role. Four cycles of 2-minute ischemia followed by 3-minute
reperfusion did not elicit protection in two separate models
of diabetes [54], compared to 3 cycles of 5-minute ischemia
and 10-minute reperfusion used by Tsang et al. [55] in the
same animal and experimental setting.
A recent study by Hotta et al. (2010) [78] using the
OLETF rat model of type II diabetes showed that pre-
treatment with either opioid agonist [79] or erythropoietin
(EPO) [80], known to mediate IPC signaling through Janus
kinase (Jak-2), failed to elicit cardioprotection in vivo due
to insuﬃcient phosphorylation of Jak-2 and Akt, and like
others, also found an elevated level of calcineurin activity
in diabetic hearts [81]. Interestingly, following 2-week treat-
ment with either valsartan or losartan, Angiotensin II recep-
tor type 1 (AT1) receptor blockers, Jak-PI3K-Akt signaling,
and hence cardioprotection subsequent to EPO administra-
tion were restored [78]. Huisamen et al. (2011) supported
theﬁndingthatAT1antagonismcanleadtocardioprotection
in their ex vivo rat model of insulin resistance, diet-induced
obesity (DIO) rat [82].
In contrast, Ghaboura et al. (2011), examined EPO-
induced IPost cardioprotection in two rat models of
type I diabetes; STZ-induced and high-fat-diet (HFD-)
induced insulin resistance syndrome. They found that EPO
administered at the onset of reperfusion did not increase
phosphorylation of Akt, ERK, or GSK-3β and hence did
not elicit a cardioprotective eﬀect in the hearts isolated
from STZ rats; interestingly, HFD rat hearts were protected
following EPO. Administration of a GSK-3β antagonist, a
kinase which is downstream of the PI3K-Akt axis, given
prior to ischemia and continued throughout reperfusion
had an infarct limiting eﬀect [83]. In support of the
idea that inhibiting GSK-3β in diabetic hearts as a direct
cardioprotectivestrategy,Grossetal.(2007)[84]showedthat
diabetes had a detrimental eﬀect on morphine-induced pro-
tection.STZ-induceddiabetescausedalterationsinpathways
upstream of GSK-3β, such as PI3K, Jak/STAT, and MAPK
pathways, limiting the cardioprotective eﬀects of morphine
administered at reperfusion. Similarly, downstream antag-
onism of GSK-3β was cardioprotective [84]. The direct
inhibition of GSK-3β was also proved cardioprotective in a
rat model of type II diabetes [85]. In this study, another
diabetic-associatedmyocardialphenotypewasreported;they
found that increased endoplasmic reticulum stress, caused10 Cardiology Research and Practice
alterations in PI3K-Akt, ERK, and GSK-3β signaling motifs,
and hence dysregulation of the mPTP leading to the absence
of cardioprotection by EPO [85].
The idea that the diabetic heart is still amenable to
protection but has an increased threshold for the necessary
activation of pro survival kinases is an interesting prospect.
Investigations by Tsang et al. [55] and Bouchard et al.
[70] clearly demonstrated this; however, in the study by
Ghaboura et al. [83] increasing the dose of EPO did not
restore cardioprotective eﬀects. Of course, these studies are
performed in a variety of models of diabetes, with variable
levels of diabetic severity. Tsang et al. [55] used a model
with moderate hyperglycemia, however both Bouchard et
al. [70] and Ghaboura et al. [83] induced diabetes by
injections of STZ at 55mg/kg and 65mg/kg, respectively.
Therefore, speculation that the ability to protect the diabetic
heart can be restored by an increased stimulus in moderate
hyperglycemia but not severe hyperglycemia could be ﬂawed
and needs further investigation.
All of the mentioned studies have furthered the under-
standing of the mechanisms that could render the diabetic
heart ineﬀective to cardioprotective strategies, and how we
could potentially overcome these hurdles. Though a variety
of animal models were used, including in vivo and ex vivo
experimental protocols, direct targeting of GSK-3β in the
diabetic heart may provide an alternative solution to prevent
ischemia reperfusion injury [86]. However, like any therapy,
a targeted approach would have to be considered to limit any
potential negative eﬀects [87].
4.2. Experimental Studies Using Human Heart Tissue. As part
of the translational process, our laboratory have established
since 1995 an isolated human atrial muscle preparation of
simulated IRI [90]. This preparation has become a popular
tool in investigating the response of human tissue in cardio-
vascular diseases. In brief, samples of right atrial appendage
are obtained from the right atrial cannula insertion site in
patients undergoing cardiac bypass during coronary artery
bypass graft surgery [91]. From the right atrial appendage,
trabeculae are isolated and subjected to simulated IRI and
the recovery of basal function assessed following IRI.
Numerous studies have been performed investigating
the mechanisms of preconditioning in the normoglycemic
human myocardium [92]; however a limited number of
studies also investigated this phenomena in the diabetic
human heart. Using a variation of this model in which the
right atrial appendage is sliced and subjected to simulated
IRI, Ghosh et al. (2001) [93], showed the failure of IPC
to protect the diabetic human myocardium with 1 cycle
of 5-minute ischemia and 5-minute reperfusion reﬂecting
what was already demonstrated in animal investigations,
that is, an increased threshold for cardioprotection in
the hyperglycemic tissue. As previously mentioned KATP
channels play a role in IPC. Diazoxide, a KATP opener, did
not mimic IPC in diabetic tissues suggesting a dysfunctional
mitochondrial KATP channel [93]. This result was supported
by the ﬁnding that the ATP-sensitive potassium channels are
altered in ventricular myocytes from diabetic rats [94]. Of
interest, this group did not try increasing the IPC stimulus to
seeifthehumanmusclemirroredtheﬁndingfromTsangand
colleagues[55].Hassounaetal.(2006)alsosuggestedthatthe
dysfunctionalmitochondrialKATP channelexistsindiabetics,
causing impaired depolarization and superoxide production,
resulting in an inability to respond to IPC [95]. Increasing
the IPC stimulus to 3 cycles in this experimental model did
not restore the protection [95], conﬂicting with the ﬁnding
of Tsang et al. [55]. However, Sivaraman et al. (2010) [88]
showed that increasing the duration of ischemic period of
IPC from 4 minutes to 7 minutes followed by reoxygenation
in human diabetic atrial tissue restored cardioprotection and
similarly was related to a downregulation of PI3K-Akt axis in
diabetic tissue [88].
In a recent study performed by Linares-Palomino et
al. speciﬁc inhibitors of Akt were utilized to delineate its
speciﬁc role in ischemic pre conditioning. They showed that
blockade of Akt caused a signiﬁcant reduction in cell death,
similar to the degree of protection elicited by either IPC or
PI3K inhibition and this was evident in both rat and human
tissue. Interestingly, they showed Akt to be downstream of
mitochondrial KATP channel but upstream of p38 MAPK
[96].
This data reinforces the fact that cardioprotection in the
diabetic heart is a complex and delicate phenomenon; the
knowledge gained from the extensive research throughout
many models has highlighted some potential reasons why it
is more diﬃcult to protect the diabetic heart, reasons which
are summarized in Figure 4.
Proof-of-concept clinical studies are now required to
determine whether the human diabetic heart is amenable to
cardioprotection elicited by ischemic conditioning. Prelimi-
nary unpublished data from our research group suggests that
thediabeticpatientmaynotbeamenabletocardioprotection
elicited by remote ischemic conditioning (RIC). There was
no diﬀerence in perioperative myocardial IRI (72 hour area
under the curve serum Troponin T) in diabetic patients
randomized to receive a standard RIC stimulus (three 5-
minute inﬂations and deﬂations of a blood pressure cuﬀ
on the upper arm) prior to CABG surgery (Babu et al.
unpublished), a RIC protocol which has been previously
reported to protect nondiabetic patients [97].
5. Limitation of Translation andFuture
Directions
The obvious limitation of translating research from bench to
bedside is that many of the animal models we use do not
adequately reproduce the clinical setting or fully represent
the disease pathology and manifestation in patients. In
addition, the vast majority of studies are conducted on
inbred animals with very little genetic variability; they are
fed ad libitum with scientiﬁc diets and are kept in optimal
living conditions of light and temperature. This is far from
the complexity of patients who possess a large genetic pool,
undergo the stresses of day to day working life, some eating
high-fat diets and undertaking limited exercise. In addition,
themajorityofpeopleinwesternizedsocietiestakeaplethora
of medications.Cardiology Research and Practice 11
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Figure 4: Why is the diabetic heart harder to protect with conditioning strategies? The diabetic heart has been suggested to have a raised
threshold for cardioprotection [55], this is caused by the downregulation of prosurvival kinase pathways [55, 88], resulting in dysregulation
of mitochondrial permeability transition pore (mPTP), increased receptor activities for pharmacological agents [78], increased calcineurin
activity [81] and evidence suggests a dysfunctional KATP channel in the mitochondria [76]. In diabetes, endoplasmic reticulum (ER) stress
also causes alterations in kinase pathways leading to dysregulation of the mPTP [85]. Interestingly, some evidence suggests that the diabetic
heart is in a paradoxical protective state therefore conditioning potential is lower [89].
There is an increasing amount of research now being
conducted in animals with comorbidities to promote suc-
cessful translation of the research ﬁeld of cardioprotection.
The design of the preclinical model, either in human tissue
or animal models, is critical to harness the huge potential
of IPC as a strategy to reduce ischemic damage. Preliminary
unpublished data from our research group, utilizing aging,
diabetic rats suggests an age-associated increase to the
threshold of IPC and susceptibility to infarction in models
of type II diabetes (Whittington et al. unpublished). These
results could highlight a possible discrepancy from original
IPC studies performed in young healthy animals and could
indicate why the ﬁndings were not transferable to the clinic.
6. Summary
It is well established that diabetic patients with IHD
experience worse clinical outcomes yet the animal data is
conﬂicting. The choice of the diabetic and IRI animal model
may in part explain this discrepancy. The development of
novel cardioprotective strategies for protecting the diabetic
heart and improving clinical outcomes in diabetic patients
withIHDwillbedependentonusingrelevantanimalmodels
of IRI and diabetes which also take into account other
comorbidities such as age, dyslipidaemia, and hypertension.
Therefore, by carefully selecting and optimizing clinically
relevant animal models of IRI and diabetes, we may be able
to better translate ﬁndings made at the “bench” to patients’
“bedside”.
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